ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ILMN Stock Price » ILMN Stock News

Illumina Share News

 Illumina (mm) Stock Price
ILMN Stock Price
 Illumina (mm) Stock Chart
ILMN Stock Chart
 Illumina (mm) Stock News
ILMN Stock News
 Illumina (mm) Company Information
ILMN Company Information
 Illumina (mm) Stock Trades
ILMN Stock Trades

Roche Criticizes Illumina's Apple Comparison

DOW JONES NEWSWIRES Swiss drug maker Roche Holding AG (ROG.VX, RHHBY) again urged Illumina Inc. (ILMN) shareholders to vote for its slate of board candidates and criticized the U.S. gene-sequencing company for comparing itself to Apple Inc. (AAPL), in Roche's latest move to stage a takeover. In a letter to Illumina shareholders Wednesday, Roche mocked Illumina for recently telling shareholders that the company has been called "the Apple of the genomics business." "There is one glaring difference between Illumina and Apple--Illumina's MiSeq and HiSeq are not the iPhone and the iPad," Roche wrote, saying Illumina's products serve a much smaller and highly regulated market compared with Apple's products. Roche noted "crowd control of eager buyers" has not been a problem for the company and "not even Illumina has projected any surge in revenues from its products in any specific foreseeable time period." Roche said Illumina has an uncertain future as a standalone company, but it is "willing to assume this risk." Last week Illumina rejected Roche's sweetened offer of $51 a share, saying the revised bid--which values the company at about $6.5 billion--was still inadequate and opportunistic. However, Roche Wednesday said its offer is "very attractive" and "a more than reasonable starting point for negotiations." Over the last week, three proxy-advisory firms have recommended that Illumina shareholders vote against Roche's board nominees. Ilumina shares slid by 13 cents to $52.44 after hours. The stock has gained 72% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287;

Stock News for Illumina (ILMN)
03/19/201519:53:52Statement of Changes in Beneficial Ownership (4)
03/18/201508:31:00Matthew Posard Joins Trovagene's Executive Management Team as...
03/16/201518:47:33Statement of Changes in Beneficial Ownership (4)
03/16/201518:22:42Statement of Changes in Beneficial Ownership (4)
03/16/201504:05:00Illumina Files Patent Infringement Suit in the United Kingdom...
03/13/201519:37:42Statement of Changes in Beneficial Ownership (4)
03/12/201517:56:41Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:34Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:34Statement of Changes in Beneficial Ownership (4)
03/11/201519:48:12Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:43Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:43Statement of Changes in Beneficial Ownership (4)
03/11/201519:47:21Statement of Changes in Beneficial Ownership (4)
03/10/201509:00:00Illumina Announces Strategic Collaboration with Merck Serono...
03/09/201503:59:30Looking Back At 2014 And What To Expect In 2015 For Sequenom
03/04/201506:30:00Illumina Launches TruSight HLA Solution
02/26/201506:30:00Illumina Accelerator Secures $40 Million Boost Capital to Back...
02/23/201506:30:00Illumina Launches the NeoPrep Library Prep System
02/18/201506:30:00Illumina to Webcast Live Presentation at the Cowen and Company...
02/13/201513:58:58Amended Statement of Ownership (sc 13g/a)

Illumina and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations